Abstract 16418: Reinitiation of Antithrombotic Therapy After Emergency Procedures or After an Uncontrolled or Life Threatening Bleeding Event. Initial Experience From the Re-verse Ad Trial
Charles V. Pollack, Jeffrey I. Weitz(McMaster University Medical Centre), Frank W. Sellke(Brown University), Menno V. Huisman(Leiden University Medical Center), Stephan Glund(Boehringer Ingelheim (Germany)), Thorsten Steiner(Heidelberg University), Jerrold H. Levy(Duke University), Peter Verhamme(KU Leuven), Robert Dubiel(Boehringer Ingelheim (Germany)), Pieter W. Kamphuisen(University Medical Center Groningen), Elaine M. Hylek(Boston University), Bushi Wang(Boehringer Ingelheim (United States)), John W. Eikelboom(Population Health Research Institute), Richard A. Bernstein(Northwestern University), Paul Reilly(Boehringer Ingelheim (United States)), Joachim Stangier(University of Bonn), Jörg Kreuzer(Boehringer Ingelheim (Germany)), CW Kam(Boehringer Ingelheim (Germany))
Cited by 5
Related Papers
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2009|11.2k
Prevalence of Diagnosed Atrial Fibrillation in Adults
|JAMA|2001|6.2k
Edoxaban versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2013|5.2k
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
|Journal of the American College of Cardiology|2020|2.9k